Article

Functional analysis of receptor tyrosine kinase mutations in lung cancer identifies oncogenic extracellular domain mutations of ERBB2

Department of Medical Oncology, Center for Cancer Genome Discovery, and Cancer Biology, Dana-Farber Cancer Institute, Boston, MA 02115.
Proceedings of the National Academy of Sciences (Impact Factor: 9.81). 08/2012; 109(36):14476-81. DOI: 10.1073/pnas.1203201109
Source: PubMed

ABSTRACT We assessed somatic alleles of six receptor tyrosine kinase genes mutated in lung adenocarcinoma for oncogenic activity. Five of these genes failed to score in transformation assays; however, novel recurring extracellular domain mutations of the receptor tyrosine kinase gene ERBB2 were potently oncogenic. These ERBB2 extracellular domain mutants were activated by two distinct mechanisms, characterized by elevated C-terminal tail phosphorylation or by covalent dimerization mediated by intermolecular disulfide bond formation. These distinct mechanisms of receptor activation converged upon tyrosine phosphorylation of cellular proteins, impacting cell motility. Survival of Ba/F3 cells transformed to IL-3 independence by the ERBB2 extracellular domain mutants was abrogated by treatment with small-molecule inhibitors of ERBB2, raising the possibility that patients harboring such mutations could benefit from ERBB2-directed therapy.

Download full-text

Full-text

Available from: D R Mani, Aug 26, 2015
0 Followers
 · 
249 Views
  • Source
    • "To explore the effect of CDCP1 downregulation, we used the immortalized but nontransformed human breast epithelial cell line MCF10A, which expresses high levels of CDCP1, but not HER2. Next, we overexpressed two previously characterized HER2 active mutations (Greulich et al., 2012) in these cells to establish two cell lines: HER2-S310F (MCF10A-HER2-S310F) and HER2-S310Y (MCF10A-HER2-S310Y). Overexpression of (D) Patients with CDCP1 and HER2 co-overexpressing tumors display a worse clinical outcome. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Understanding the molecular pathways that contribute to the aggressive behavior of HER2-positive breast cancers may aid in the development of novel therapeutic interventions. Here, we show that CDCP1 and HER2 are frequently co-overexpressed in metastatic breast tumors and associated with poor patient prognosis. HER2 and CDCP1 co-overexpression leads to increased transformation ability, cell migration, and tumor formation in vivo, and enhanced HER2 activation and downstream signaling in different breast cancer cell lines. Mechanistically, we demonstrate that CDCP1 binds to HER2 through its intracellular domain, thereby increasing HER2 interaction with the non-receptor tyrosine kinase c-SRC (SRC), leading to trastuzumab resistance. Taken together, our findings establish that CDCP1 is a modulator of HER2 signaling and a biomarker for the stratification of breast cancer patients with poor prognosis. Our results also provide a rationale for therapeutic targeting of CDCP1 in HER2-positive breast cancer patients. Copyright © 2015 The Authors. Published by Elsevier Inc. All rights reserved.
    Cell Reports 04/2015; 18(4). DOI:10.1016/j.celrep.2015.03.044 · 8.36 Impact Factor
  • Source
    • "MEK, Akt, PI3K, mTOR or STAT3. For instance, in a bladder cancer cell line (5637), harbouring a S310F mutation of HER2, afatinib alone had a little effect on cell survival, but in the presence of an inhibitor of MEK, which did not affect survival on its own, afatinib became a 10-fold more potent inhibitor (Greulich et al. 2012). In an NSCLC model (H1975, EGFR T790M), combinations of afatinib with a MEK inhibitor (PD032901), a SRC inhibitor (dasatinib) or a PI3K inhibitor (PI-103) showed additive effects on induction of apoptosis, although this did not reach statistical significance (Sos et al. 2010). "
    [Show abstract] [Hide abstract]
    ABSTRACT: Afatinib (also known as BIBW 2992) has recently been approved in several countries for the treatment of a distinct type of epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer. This manuscript comprehensively reviews the preclinical data on afatinib, an irreversible inhibitor of the tyrosine kinase activity of members of the epidermal growth factor receptor family (ErbB) including EGFR, HER2 and ErbB4. Afatinib covalently binds to cysteine 797 of the EGFR and the corresponding cysteines 805 and 803 in HER2 and ErbB4, respectively. Such covalent binding irreversibly inhibits the tyrosine kinase activity of these receptors, resulting in reduced auto- and transphosphorylation within the ErbB dimers and inhibition of important steps in the signal transduction of all ErbB receptor family members. Afatinib inhibits cellular growth and induces apoptosis in a wide range of cells representative for non-small cell lung cancer, breast cancer, pancreatic cancer, colorectal cancer, head and neck squamous cell cancer and several other cancer types exhibiting abnormalities of the ErbB network. This translates into tumour shrinkage in a variety of in vivo rodent models of such cancers. Afatinib retains inhibitory effects on signal transduction and in vitro and in vivo cancer cell growth in tumours resistant to reversible EGFR inhibitors, such as those exhibiting the T790M mutations. Several combination treatments have been explored to prevent and/or overcome development of resistance to afatinib, the most promising being those with EGFR- or HER2-targeted antibodies, other tyrosine kinase inhibitors or inhibitors of downstream signalling molecules.
    Archiv für Experimentelle Pathologie und Pharmakologie 03/2014; 387(6). DOI:10.1007/s00210-014-0967-3 · 2.36 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Protein phosphorylation plays key roles in the regulation of normal and cancer cells. It is a highly dynamic process. Protein kinases are the targets of several new cancer drugs and drug candidates. However, some of the main issues related to new drugs are how they function and the selection of those patients that will likely respond best to a particular treatment regime. There is an urgent need to understand and monitor kinase signalling pathways. Phosphoproteomics requires the enrichment of phosphorylated proteins or peptides from tissue or bodily fluids, and the application of technologies such as mass spectrometry (MS) to the identification and quantification of protein phosphorylation sites. As the field develops it will provide pharmacodynamic readouts of disease states and cellular drug responses in tumour samples. There have been a number of recent advances, but there are still technical hurdles and bioinformatics challenges that need to be addressed.
    Clinical and Translational Oncology 07/2009; 11(6):356-62. · 2.08 Impact Factor
Show more